Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
Allarity Therapeutics (NASDAQ: ALLR) has announced a $5 million share repurchase program authorized by its Board of Directors, running through February 28, 2026. The company, currently in Phase 2 clinical trials, is developing stenoparib—a dual PARP/Wnt pathway inhibitor—for personalized cancer treatment using its Drug Response Predictor (DRP®) technology.
The repurchase program, which will be executed through open market transactions, reflects management's confidence in the company's direction and its commitment to shareholder value. As disclosed in November 2024, Allarity's cash position extends into 2026, allowing the company to proceed with the buyback without impacting its financial runway.
The company is preparing to initiate patient enrollment for stenoparib trials in advanced ovarian cancer, focusing on investigating its dual mechanisms as both a PARP inhibitor and Wnt pathway modulator.
Allarity Therapeutics (NASDAQ: ALLR) ha annunciato un programma di riacquisto di azioni da 5 milioni di dollari autorizzato dal suo Consiglio di Amministrazione, valido fino al 28 febbraio 2026. L'azienda, attualmente in fase di sperimentazione clinica di Fase 2, sta sviluppando stenoparib—un inibitore duale della via PARP/Wnt—per il trattamento personalizzato del cancro utilizzando la sua tecnologia Drug Response Predictor (DRP®).
Il programma di riacquisto, che sarà eseguito tramite transazioni di mercato aperto, riflette la fiducia della direzione nella direzione dell'azienda e il suo impegno verso il valore per gli azionisti. Come comunicato nel novembre 2024, la posizione di liquidità di Allarity si estende fino al 2026, consentendo all'azienda di procedere con il riacquisto senza influenzare la sua capacità finanziaria.
L'azienda si sta preparando ad avviare l'arruolamento dei pazienti per le sperimentazioni di stenoparib nel cancro ovarico avanzato, concentrandosi sull'indagine dei suoi meccanismi duali sia come inibitore della PARP che come modulatore della via Wnt.
Allarity Therapeutics (NASDAQ: ALLR) ha anunciado un programa de recompra de acciones de 5 millones de dólares autorizado por su Junta Directiva, que se extenderá hasta el 28 de febrero de 2026. La compañía, actualmente en ensayos clínicos de Fase 2, está desarrollando stenoparib—un inhibidor dual de la vía PARP/Wnt—para el tratamiento personalizado del cáncer utilizando su tecnología Drug Response Predictor (DRP®).
El programa de recompra, que se ejecutará a través de transacciones en el mercado abierto, refleja la confianza de la dirección en la dirección de la empresa y su compromiso con el valor para los accionistas. Como se reveló en noviembre de 2024, la posición de efectivo de Allarity se extiende hasta 2026, lo que permite a la empresa proceder con la recompra sin afectar su capacidad financiera.
La compañía se está preparando para iniciar la inscripción de pacientes para los ensayos de stenoparib en cáncer de ovario avanzado, centrándose en investigar sus mecanismos duales tanto como inhibidor de PARP como modulador de la vía Wnt.
Allarity Therapeutics (NASDAQ: ALLR)는 이사회에서 승인한 500만 달러 규모의 자사주 매입 프로그램을 발표했으며, 이는 2026년 2월 28일까지 진행됩니다. 현재 2상 임상 시험 중인 이 회사는 개인 맞춤형 암 치료를 위해 PARP/Wnt 경로의 이중 억제제인 stenoparib을 개발하고 있습니다. 이 과정에서 Drug Response Predictor (DRP®) 기술을 사용합니다.
매입 프로그램은 공개 시장 거래를 통해 실행되며, 이는 경영진이 회사의 방향에 대한 신뢰와 주주 가치를 향한 헌신을 반영합니다. 2024년 11월에 발표된 바와 같이, Allarity의 현금 보유량은 2026년까지 연장되어 있어 재정적 여유에 영향을 주지 않고 매입을 진행할 수 있습니다.
회사는 고급 난소암에 대한 stenoparib 시험을 위한 환자 등록을 시작할 준비를 하고 있으며, PARP 억제제이자 Wnt 경로 조절제로서의 이중 메커니즘을 조사하는 데 집중하고 있습니다.
Allarity Therapeutics (NASDAQ: ALLR) a annoncé un programme de rachat d'actions de 5 millions de dollars autorisé par son Conseil d'Administration, qui s'étendra jusqu'au 28 février 2026. L'entreprise, actuellement en phase d'essai clinique de phase 2, développe le stenoparib—un inhibiteur dual de la voie PARP/Wnt—pour un traitement personnalisé du cancer utilisant sa technologie Drug Response Predictor (DRP®).
Le programme de rachat, qui sera exécuté par le biais de transactions sur le marché ouvert, reflète la confiance de la direction dans l'orientation de l'entreprise et son engagement envers la valeur pour les actionnaires. Comme divulgué en novembre 2024, la position de liquidités d'Allarity s'étend jusqu'en 2026, permettant à l'entreprise de procéder au rachat sans affecter sa capacité financière.
L'entreprise se prépare à initier l'inscription des patients pour les essais de stenoparib dans le cancer de l'ovaire avancé, en se concentrant sur l'exploration de ses mécanismes duals en tant qu'inhibiteur de PARP et modulateur de la voie Wnt.
Allarity Therapeutics (NASDAQ: ALLR) hat ein Aktienrückkaufprogramm im Wert von 5 Millionen Dollar angekündigt, das von seinem Vorstand genehmigt wurde und bis zum 28. Februar 2026 läuft. Das Unternehmen, das sich derzeit in der Phase-2-Studie befindet, entwickelt stenoparib—einen dualen Inhibitor des PARP/Wnt-Weges—für die personalisierte Krebsbehandlung unter Verwendung seiner Drug Response Predictor (DRP®) Technologie.
Das Rückkaufprogramm, das durch Transaktionen auf dem offenen Markt durchgeführt wird, spiegelt das Vertrauen des Managements in die Richtung des Unternehmens und sein Engagement für den Shareholder-Value wider. Wie im November 2024 bekannt gegeben, reicht die Liquiditätsposition von Allarity bis 2026, was dem Unternehmen ermöglicht, den Rückkauf durchzuführen, ohne seine finanzielle Stabilität zu beeinträchtigen.
Das Unternehmen bereitet sich darauf vor, die Patientenrekrutierung für die stenoparib-Studien bei fortgeschrittenem Eierstockkrebs zu beginnen, wobei der Fokus auf der Untersuchung seiner dualen Mechanismen sowohl als PARP-Inhibitor als auch als Modulator des Wnt-Weges liegt.
- Board authorized $5M share repurchase program through Feb 2026
- Strong cash position extending into 2026
- Advancing Phase 2 clinical trials for stenoparib
- Dual mechanism drug (PARP/Wnt pathway inhibitor)
- No guarantee of specific number of shares to be repurchased
- Program may be modified or discontinued at company's discretion
Insights
Allarity Therapeutics' $5 million share repurchase program represents a significant financial commitment for this clinical-stage biotech, especially considering the company's market cap of only $3.6 million. This authorization effectively allows the company to repurchase more than its entire current market capitalization over the program's duration through February 2026.
The announcement signals strong management confidence in Allarity's underlying value and suggests executives believe the current share price substantially undervalues the company's assets and future potential. With shares trading at
Particularly noteworthy is the company's statement about maintaining its financial runway into 2026 even while executing this program. This indicates Allarity has sufficient cash reserves to fund both operations and share repurchases without compromising its clinical development plans for stenoparib in ovarian cancer.
For investors, this program creates potential price support for the stock while reducing the overall share count, which could lead to improved earnings per share metrics if the company's clinical programs advance successfully. However, the unusual size of the repurchase relative to market cap warrants careful monitoring of execution and impact on liquidity.
Allarity's focus on stenoparib's dual mechanism as both a PARP inhibitor and Wnt pathway modulator represents a scientifically differentiated approach in oncology. PARP inhibitors have established efficacy in ovarian cancer treatment by targeting DNA repair mechanisms in cancer cells, particularly those with BRCA mutations, while Wnt pathway signaling is increasingly recognized for its role in cancer stem cell maintenance and therapeutic resistance.
The company's upcoming trial appears strategically designed to validate their Drug Response Predictor (DRP®) technology—a biomarker-guided approach that aims to identify patients most likely to respond to stenoparib. This personalized medicine approach could potentially address a significant challenge in PARP inhibitor therapy: identifying responders beyond those with BRCA mutations.
From a clinical perspective, the advancement to patient enrollment in this Phase 2 program is a meaningful milestone. The study's dual focus on stenoparib's clinical benefit in a well-defined ovarian cancer population while simultaneously investigating its effects on Wnt signaling could generate valuable mechanistic insights and potentially expand its application to other malignancies where Wnt dysregulation plays a role.
The company appears to be pursuing a targeted development strategy that aligns with current trends toward precision oncology and biomarker-guided therapy selection.
Boston (March 3, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that its Board of Directors has authorized a share repurchase program, allowing for the repurchase of up to
The decision underscores the Company’s confidence in its future trajectory and dedication to delivering value to both patients and shareholders.
As previously disclosed on November 14, 2024, Allarity’s cash position allows it to maintain a financial runway extending into 2026. The Company remains sufficiently capitalized to proceed with the share repurchase program without affecting this runway.
“The Board’s decision to authorize a share repurchase program of up to
Under the authorization, Allarity may repurchase shares at its discretion from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions and compliance with applicable legal requirements. Repurchases may be made through open market transactions or other methods as permitted by securities laws and regulations, including Rule 10b-18 under the Securities Exchange Act of 1934, as amended.
The share repurchase program does not obligate Allarity to acquire any specific number of shares and may be modified, suspended, or discontinued at any time at the Company’s discretion.
About Stenoparib
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, are found to have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in the peer-reviewed literature.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
X: https://twitter.com/allaritytx
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the implementation of Allarity’s new Phase 2 trial protocol, its potential to generate key clinical insights into stenoparib’s efficacy and mechanism of action, and the Company’s ability to advance the development of stenoparib and its companion diagnostic, stenoparib-DRP, for the treatment of advanced ovarian cancer. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the successful execution of the Phase 2 trial, regulatory barriers, patient enrollment and retention challenges, clinical trial outcomes, and the Company’s ability to secure additional funding and partnerships to support ongoing development efforts, including the continued development of stenoparib and stenoparib-DRP. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form S-1/A registration statement filed on April 17, 2024, our Form 10-K annual report on file with the Securities and Exchange Commission (the “SEC”) and our Form 10-Q quarterly report filed with the SEC on November 14, 2024, available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
###
Company Contact:
investorrelations@allarity.com
Media Contact:
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Attachment
FAQ
What is the size and duration of Allarity Therapeutics' (ALLR) share repurchase program?
How will ALLR's share repurchase program affect its financial runway?
What is the current development stage of Allarity's (ALLR) stenoparib drug?
How will ALLR implement its share repurchase program?
